ES2181208T3 - Analogos de nucleosidos de pirimidina antivirales. - Google Patents

Analogos de nucleosidos de pirimidina antivirales.

Info

Publication number
ES2181208T3
ES2181208T3 ES98919313T ES98919313T ES2181208T3 ES 2181208 T3 ES2181208 T3 ES 2181208T3 ES 98919313 T ES98919313 T ES 98919313T ES 98919313 T ES98919313 T ES 98919313T ES 2181208 T3 ES2181208 T3 ES 2181208T3
Authority
ES
Spain
Prior art keywords
group
alkyl
halogens
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98919313T
Other languages
English (en)
Inventor
Christopher Mcguigan
Christopher Yarnold
Garry Jones
Jan Balzarini
Clercq Erik De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rega Foundation
University College Cardiff Consultants Ltd
Cardiff University
Original Assignee
Rega Foundation
University College Cardiff Consultants Ltd
Cardiff University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rega Foundation, University College Cardiff Consultants Ltd, Cardiff University filed Critical Rega Foundation
Application granted granted Critical
Publication of ES2181208T3 publication Critical patent/ES2181208T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a un compuesto de formula (I) en la que : R es seleccionado en el grupo formado por un aqluilo de C{sub,5} a C{sub,20; un cicloalquilo de C{sub,5} a C{sub,20}, halógenos, un arilo y un alquilarilo; R'' es seleccionado en el grupo formado por un hidrógeno, un alquilo, un cicloalquilo, halógenos, un amino, un alquilamino, un dialquilamino, un nitro, un ciano, un alquioxi, ariloxi, un tilo, un alquiltiol, un ariltiol, un alquilo: R" es seleccionado en el grupo formado por un hidrógeno, un alquilo, un cicloalquilo, halógenos, un alquiloxi, un ariloxi y un arilo; Q es seleccionado en el grupo formado por O, S y CY{sub,2}, e el que Y puede ser el mismo o ser diferente y se selecciona en el grupo formado por H, un arilo y halógenos; X es seleccionado en el grupo formado por O, NH, S, N-Alquilo, (CH{{sub,2}){sub,n}, en el que n representa un número de 1 a 10, y CY{sub,2}, pudiendo Y ser el mismo o diferente y se selecciona a partir de un hidrógeno, representa un alquilo y halógenos; Z es seleccionado en el grupo formado por O, S, NH y N-alquilo; U" representa H y U'' es seleccionado en el grupo formado por H y CH{sub,2}T, o U'' y U" se unen para formar una fracción de núcleo que comprende Q en la que U''-U" tomados juntos son respectivamente seleccionados en el grupo formado por -CTH-CT''T- y -CT=CT- y CT''=CT'', para formar fracciones de núcleo seleccionadas en el grupo formado por las fórmulas (II) y (III), en el que T es seleccionado en el grupo formado por OH, H, halógenos, O-alquilo. O-acilo, O-arilo, CN, NH{sub,2} y N{sub,3}; T'' es seleccionado en el grupo formado por H y halógenos y donde si hay más de un T'', pueden ser los mismos o diferentes; T" es seleccionado en el grupo formado por H y halógenos, y W es seleccionado en el grupo formado por H, un grupo fosfato y una sal farmacológicamente aceptable, un derivado o un promedicamento que presenta una actividad antiviral potente contra por ejemplo el herpesvirus varicellae y el citomegalovirus.
ES98919313T 1997-04-28 1998-04-27 Analogos de nucleosidos de pirimidina antivirales. Expired - Lifetime ES2181208T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9708611.0A GB9708611D0 (en) 1997-04-28 1997-04-28 Chemical compounds

Publications (1)

Publication Number Publication Date
ES2181208T3 true ES2181208T3 (es) 2003-02-16

Family

ID=10811493

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98919313T Expired - Lifetime ES2181208T3 (es) 1997-04-28 1998-04-27 Analogos de nucleosidos de pirimidina antivirales.

Country Status (13)

Country Link
US (1) US6573247B1 (es)
EP (1) EP0980377B1 (es)
JP (1) JP4514242B2 (es)
AT (1) ATE221543T1 (es)
AU (1) AU737902B2 (es)
CA (1) CA2288147C (es)
DE (1) DE69806919T2 (es)
DK (1) DK0980377T3 (es)
ES (1) ES2181208T3 (es)
GB (1) GB9708611D0 (es)
NZ (1) NZ500881A (es)
PT (1) PT980377E (es)
WO (1) WO1998049177A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9708611D0 (en) * 1997-04-28 1997-06-18 Univ Cardiff Chemical compounds
GB9716231D0 (en) 1997-07-31 1997-10-08 Amersham Int Ltd Base analogues
ATE413881T1 (de) 1997-08-08 2008-11-15 Celmed Oncology Usa Inc Verfahren und zubereitungen um resistenz gegen biologische oder chemische therapien zu überwinden
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
ES2172303T3 (es) 1998-01-23 2002-09-16 Newbiotics Inc Agentes terapeuticos obtenidos por catalisis enzimatica.
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
IL147749A0 (en) 1999-07-22 2002-08-14 Newbiotics Inc Methods for treating therapy-resistant tumors
GB0009486D0 (en) 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
GB0011203D0 (en) * 2000-05-09 2000-06-28 Univ Cardiff Chemical compounds
US7144995B2 (en) 2002-03-08 2006-12-05 Glen Research Corporation Fluorescent nitrogenous base and nucleosides incorporating same
AU2003298658A1 (en) 2002-11-15 2004-06-15 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
GB0609178D0 (en) 2006-05-09 2006-06-21 Univ Cardiff Novel compounds
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP3406613A1 (en) 2009-10-16 2018-11-28 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
JP6274723B2 (ja) 2009-10-16 2018-02-07 メリンタ セラピューティクス，インコーポレイテッド 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法
JP2013508299A (ja) 2009-10-16 2013-03-07 リブ−エックス ファーマシューティカルズ，インコーポレイテッド 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
EP3404028A1 (en) 2011-04-15 2018-11-21 Melinta Therapeutics, Inc. Methods of making antimicrobial compounds
GB201111779D0 (en) 2011-07-08 2011-08-24 Univ Cardiff Chemical compounds
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
AR089650A1 (es) 2011-10-14 2014-09-10 Idenix Pharmaceuticals Inc Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
MD20140134A2 (ro) 2012-05-22 2015-04-30 Idenix Pharmaceuticals, Inc. Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
PT2861611T (pt) 2012-05-25 2016-10-11 Janssen Sciences Ireland Uc Nucleósidos de espirooxetano de uracilo
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
ES2674980T3 (es) 2012-10-08 2018-07-05 Idenix Pharmaceuticals Llc Análogos de 2'-cloro nucleósidos para infección por VHC
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
EP2970357B1 (en) 2013-03-13 2025-01-01 Idenix Pharmaceuticals LLC Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
US9937183B2 (en) 2013-09-09 2018-04-10 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
MX2016002975A (es) 2013-09-09 2016-10-21 Melinta Therapeutics Inc Compuestos antimicrobianos y métodos de fabricación y utilización de los mismos.
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
WO2016145417A1 (en) 2015-03-11 2016-09-15 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
US11098047B2 (en) 2016-05-06 2021-08-24 BioVersys AG Antimicrobials and methods of making and using same
EP4337646A4 (en) * 2021-05-13 2025-05-21 Promega Corporation BIOLUMINESCENT DETECTION OF DNA SYNTHESIS
US20260062437A1 (en) * 2022-08-26 2026-03-05 Regents Of The University Of Minnesota Antiviral compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62255499A (ja) 1986-04-28 1987-11-07 Teijin Ltd 螢光性ヌクレオシド又はヌクレオチド
US5047519A (en) * 1986-07-02 1991-09-10 E. I. Du Pont De Nemours And Company Alkynylamino-nucleotides
GB9109186D0 (en) * 1991-04-29 1991-06-19 Wellcome Found Preparation of thionucleosides
YU43193A (sh) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
JPH06192285A (ja) * 1992-12-25 1994-07-12 Yamasa Shoyu Co Ltd １−（β−Ｄ−エリスロ−ペントフラン−２−ウロシル）ピリミジン誘導体の製造法
DE4321978A1 (de) * 1993-07-01 1995-01-12 Boehringer Mannheim Gmbh Liponucleotide von Desoxynucleosiden, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
GB9708611D0 (en) * 1997-04-28 1997-06-18 Univ Cardiff Chemical compounds
GB9716231D0 (en) * 1997-07-31 1997-10-08 Amersham Int Ltd Base analogues
HK1053126A1 (zh) * 1999-07-22 2003-10-10 新生物生物公司 酶催化的治疗活化
JP2003527317A (ja) * 1999-07-22 2003-09-16 ニューバイオティックス インコーポレイテッド 酵素触媒抗感染性治療剤
IL147749A0 (en) * 1999-07-22 2002-08-14 Newbiotics Inc Methods for treating therapy-resistant tumors

Also Published As

Publication number Publication date
NZ500881A (en) 2001-11-30
DE69806919D1 (de) 2002-09-05
AU7219398A (en) 1998-11-24
DK0980377T3 (da) 2002-11-18
EP0980377A1 (en) 2000-02-23
JP2001522369A (ja) 2001-11-13
ATE221543T1 (de) 2002-08-15
DE69806919T2 (de) 2003-02-27
CA2288147A1 (en) 1998-11-05
AU737902B2 (en) 2001-09-06
WO1998049177A1 (en) 1998-11-05
WO1998049177A8 (en) 2000-01-13
PT980377E (pt) 2002-12-31
CA2288147C (en) 2008-03-11
GB9708611D0 (en) 1997-06-18
JP4514242B2 (ja) 2010-07-28
US6573247B1 (en) 2003-06-03
EP0980377B1 (en) 2002-07-31

Similar Documents

Publication Publication Date Title
DE69806919D1 (de) Antivirale pyrimidin-nukleosid-analogen
TR200400785T4 (tr) Antivirütik pirimidin nükleosid analogları
CA2200316A1 (en) Imidazole derivative
BR9815166A (pt) "método de inibição da replicação de vìrus, composto, método de inibição da replicação de citomegalovìrus, composto antiviral, utilização de um composto, composição farmacêutica, composição farmacêutica inibidora da replicação de vìrus e de citomegalovìrus e composição farmacêutica antiviral"
KR950032263A (ko) 2'-에테르 그룹을 갖는 뉴클레오사이드 및 올리고 뉴클레오타이드
CA2171275A1 (en) Stilbene derivatives and pharmaceutical compositions containing them
CA2078790A1 (en) 3-benzylidene-1-carbamoyl-2-pyrrolidone analogues
IL103844A (en) Rebeccamycin analogs, their preparation and pharmaceutical compositions containing them
DK0545966T3 (da) Phospholipidderivater af nucleosider, deres fremstilling samt deres anvendelse som anti-virale lægemidler
IL86040A (en) Acid stable purine dideoxynu- cleosides, their preparation and pharmaceutical compositions containing them
ATE247654T1 (de) Neue heterozyklische verbindungen
ATE295849T1 (de) Aryl-ester phosphoramidatderivate von 2',3'- didehydronukleoside
HU9401221D0 (en) New heterocyclic compounds
EP0638567A4 (en) ADENOSINE INHIBITORS.
TW369536B (en) Phosphonate nucleotide compounds
EP0291917A3 (en) Novel oxetanocins
CA2038934A1 (en) Anti-cancer compounds
WO2001026629A3 (en) Neutral-cationic lipid for nucleic acid and drug delivery
ES2142773A1 (es) Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia desminuida.
TW360652B (en) Acryloyl substituted disstamycin derivatives, process for preparing them, and pharmaceutical composition comprising them
ATE36331T1 (de) Guanin-derivate, diese enthaltende zusammensetzungen und ihre antivirale wirkung.
ES8300768A1 (es) "procedimiento para la preparacion de nuevas pirimido (5,4-d) pirimidinas trisustituidas".
GB1509300A (en) Ethanolamine derivatives
MX9303990A (es) Tetrazolil (fenoxi y fenoxialquil) piperidinil piridazinas como agentes antivirales.
IE832001L (en) IMIDAZO £1,2-a| PYRIMIDINES.